Ellevest Inc. Has $524,000 Stake in Pfizer Inc. (NYSE:PFE)

Ellevest Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 19,767 shares of the biopharmaceutical company’s stock after selling 2,681 shares during the quarter. Ellevest Inc.’s holdings in Pfizer were worth $524,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Ensign Peak Advisors Inc grew its holdings in shares of Pfizer by 27.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 6,445,011 shares of the biopharmaceutical company’s stock valued at $170,986,000 after acquiring an additional 1,383,305 shares in the last quarter. Ethic Inc. grew its stake in Pfizer by 40.4% in the fourth quarter. Ethic Inc. now owns 449,474 shares of the biopharmaceutical company’s stock valued at $11,925,000 after purchasing an additional 129,381 shares in the last quarter. Fairfax Financial Holdings Ltd. Can increased its position in Pfizer by 41.2% in the 4th quarter. Fairfax Financial Holdings Ltd. Can now owns 650,900 shares of the biopharmaceutical company’s stock worth $17,275,000 after purchasing an additional 190,000 shares during the last quarter. Fred Alger Management LLC raised its stake in shares of Pfizer by 13.4% during the 4th quarter. Fred Alger Management LLC now owns 116,411 shares of the biopharmaceutical company’s stock worth $3,088,000 after purchasing an additional 13,743 shares in the last quarter. Finally, Cladis Investment Advisory LLC grew its stake in shares of Pfizer by 8.7% in the 4th quarter. Cladis Investment Advisory LLC now owns 63,174 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 5,036 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PFE shares. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

Pfizer Price Performance

NYSE:PFE opened at $22.28 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $126.36 billion, a P/E ratio of 15.80, a PEG ratio of 0.64 and a beta of 0.58. The company has a fifty day moving average price of $24.02 and a 200 day moving average price of $25.56. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter last year, the company earned $0.82 earnings per share. The firm’s revenue was down 7.8% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.72%. Pfizer’s payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.